Skip to main content
. 2021 Mar 15;12(10):2886–2892. doi: 10.7150/jca.47566

Figure 1.

Figure 1

Detection of CD163 expression in breast cancer tissue and adjacent normal tissue by immunohistochemistry. Strong CD163 immunoreactivity was identified in aggressive cancer (E, F), weak immunoreactivitywas identified in low or moderate cancer(C, D) and barely seen in normal tissue (A, B).